$69 postpage LB

Why Orthocell (ASX:OCC) should be on investors’ radar today?

  • January 14, 2021 10:53 AM AEDT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2314 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

Why Orthocell (ASX:OCC) should be on investors’ radar today?

Summary

  • Orthocell has received FDA 510(k) clearance to market and supply its CelGro device in the US market.
  • It is an approved device which helps in the dental bone and tissue regeneration procedures.
  • Managing Director of Orthocell, Paul Anderson considers this approval to be an inflection point for the company.
Gold MTF non-AMP

On 14 January 2021, Orthocell Limited (ASX:OCC) has announced that it has been granted FDA 510(k) clearance to go ahead with its CelGro collagen medical device's supply and marketing. The company plans to use the device in the procedures related to bone and tissue regeneration in the US.

The clearance follows the application submitted in May 2020. The FDA determined that the company’s Striate+ (previously branded as CelGro® Dental) is significantly equivalent to a predicate device and therefore is marketable in the US. The nod from the regulator would now allow the company to supply Striate+ in the US dental market, which is estimated to be a US$500 million per annum market.

About Striate+

Striate+ has been manufactured in good manufacturing practices (GMP) licensed manufacturing facility in WA using its proprietary SMARTTM manufacturing technology. The company believes it is a breakthrough product in its market as its clinical trials have shown it can drastically cut down the time taken to transition from two-stage to single-stage dental procedure. This massively improves the efficiency and efficacy of dental procedures.

Striate+ is an approved device in the dental bone and tissue regeneration procedures such as augmentation around dental implants in immediate and delayed extraction sockets. Striate+ has been designed on feedback from surgeons and have distinct advantages over the similar available products. Overall, it can assist surgeons in the superior handling of the procedures to deliver an improved patient outcome.

Read More: Orthocell (ASX:OCC) Share Riding High on Positive Results from Nerve Repair Trial

Management Commentary

Paul Anderson, Managing Director of Orthocell acknowledged that the FDA approval has come sooner than the expectations and would prove to be an inflection point for the company.

The management is also looking forward to working with leading dental surgeons to introduce Striate+ and make a meaningful impact in the US market.

Stock Performance

During the last three months, Orthocell’s share price has delivered a decent return of 17.9 per cent but the last one-year return stands at negative 1.07 per cent.

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK